Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2018—Genentech announced the FDA’s approval of Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors.
December 2017—ThyroSeq, a joint partnership between UPMC and CBLPath, announced the results of a double-blind, multicenter international study validating the performance of ThyroSeq V3 in thyroid nodules with indeterminate cytology. The results were presented at the 87th Annual Meeting of the American Thyroid Association, Oct. 18–22, in Victoria, British Columbia, Canada.
December 2017—Vector Laboratories introduced the ImmPress Duet Double-Staining Polymer Kit for immunohistochemistry. The kit enables fast, well-defined localization and visualization of two different target antigens on the same tissue section.
December 2017—Agena Bioscience announced a comparative study published in PLOS One (Sutton BC, et al. 2017;12[9]:e0183715) highlighting the use of its mass-spectrometry-based platform and iPlex HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer.
December 2017—Prometheus Laboratories introduced Prometheus Monitr Crohn’s Disease, a serum test that measures and monitors mucosal healing status in Crohn’s disease patients. The test can be used as an adjunct to endoscopy or by itself, between endoscopies, allowing for more frequent, noninvasive monitoring.
December 2017—Streck and Orgentec Sasu, a distributor in France that specializes in the in vitro diagnosis of autoimmunity, infectious diseases, molecular biology, internal/external quality control, biochemistry, and sedimentation rate, have signed an exclusive distribution agreement for Streck’s cell stabilization and molecular products.
December 2017—Binding Site’s Immunologicals Group has added eight recombinant antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The recombinant Parvovirus NS1, Parvovirus VP1, Parvovirus VP2, Parvovirus VP2-VLP, Parvovirus PepA (VP1 unique), Parvovirus PepB (VP2 C-term), Parvovirus PepC (VP1 N-term), and Parvovirus PepD (VP1 C-term) have been designed for use as an integral component within solid phase enzyme immunoassay test procedures, including ELISA.
December 2017—Horizon Discovery’s Dharmacon announced the launch of its CRISPR activation reagent platform, the latest addition to the company’s Edit-R portfolio for CRISPR-Cas9 genome engineering.
December 2017—Chembio Diagnostics received FDA emergency use authorization for its DPP Zika System. The system, for use in high- and moderate-complexity CLIA-certified laboratories, provides results in 15–20 minutes from 10 µL of blood and includes the DPP Zika IgM Assay and DPP Micro Reader.
December 2017—Beckman Coulter Diagnostics announced its Access 2 immunoassay system is available with enhanced features that aim to improve ease of use, workflow efficiencies, system reliability, and customer satisfaction.
